Vasodilator therapy of cardiac failure: (first of two parts).
D001808:Blood Vessels / Q000187:drug effects / Q000294:innervation; D004232:Diuretics / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006352:Heart Ventricles / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D009566:Nitrates / Q000627:therapeutic use; D005996:Nitroglycerin / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D014294:Trimethaphan / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*
D004232:Diuretics; D009566:Nitrates; D014665:Vasodilator Agents; D009599:Nitroprusside; D006830:Hydralazine; D014294:Trimethaphan; D005996:Nitroglycerin; D010646:Phentolamine